

G-FACTOR
G-Factor is a reactive environment whose aim is to support new entrepreneurs and researchers with high entrepreneurial potential to become companies able to successfully establish themselves in the market, creating replicable and scalable models. Three years after its establishment, G-Factor has consolidated its position as an accelerator for start-ups in the life sciences sector, while opening up to other vertical sectors.
We invest in innovative start-ups and teams by providing capital and expertise because we believe that the mix of finance and training is crucial to entrepreneurial success.
I-Tech Innovation Programme 2021 Download report
I-Tech Innovation 2021 is the new programme promoted by Fondazione Golinelli and CRIF. In the previous two editions, 15 start-ups in the Life Sciences sector were funded and accelerated, selected from over 250 applications with an investment of €1,625,000. Thanks to the partnership between the Fondazione and CRIF, G-Factor is now inaugurating two new verticals: FinTech & InsureTech and AgriTech & FoodTech, in addition to Life Sciences & Digital Health.
The 2021 Call, with an investment budget of €1,610,000, aims to select the next batch of 13 start-ups of which:
- five from the field of Life Sciences & Digital Health
- five from the world of FinTech & InsurTech
- three from the sectors of AgriTech & FoodTech.
The call is open to all researchers, independent teams and start-ups that wish to turn their projects into an entrepreneurial reality. Selected teams will have access to G-Force 2021, the customised Acceleration Programme offering investment, mentoring and business networking.


Calendario
IDENTIKIT LIFE SCIENCE INNOVATION 2020







G-FORCE
An innovative Acceleration Programme tailored to entrepreneurs in the Life Sciences, Fintech & Insuretech and Agritech sectors. The programme aims to accelerate the most talented teams with a high degree of innovation and a relevant technical-scientific profile, with special focus on the business dimension.
G-Force has a total duration of eight months.
For the first three months, the acceleration foresees intensive training and daily mentoring activities, with a mixed formula between remote and residential modes; for the following five months, follow-up activities with remote mentoring one day a week are foreseen.
The 2021 acceleration itinerary is tailor-made for the three specialisation areas of the start-ups that will be selected. The programme includes face-to-face webinars, workshops, mentoring and coaching tailored to each business project, concerning all strategic issues for business development. In the second part of the programme, ad-hoc networking events are foreseen to allow new start-ups and potential industrial partners and investors to meet and create connections.
WELCOME KIT
- Access to a network of highly qualified mentors and partners
- Access to a network of investors
- Legal and patent support
- Regulatory advice
- Media Coverage & Communications
- Accomodation for residential phase (when covid-19 emergency will be end)
Network
We collaborate with dozens of entrepreneurs, teachers and managers with different specializations and professional backgrounds to cover all the needs of accelerated startups: from product development to business storytelling, from IP to negotiation, from hard skills to soft skills.
Our industrial partners are important international players in the world of life sciences operating in different business areas: from pharmaceutical to medical devices, from biotech to data science. Together with our industrial partners we help startups to create sustainable and scalable businesses.
Our network is enriched by the presence of research centers, startups, companies and universities that make innovation their daily mission.
Portfolio
124 applications have been received for the first call of G-Factor, Life Sciences Innovation : 30 of these have reached the final stage and 10 have been selected to participate in the acceleration process which has end in December 2019 with the awaited Investor Day. Each Startup has received an investment of €100,000 €


BCI deals with the biocompatibility of cardiac valve substitutes manufactured with animal tissues, improving their performance and doubling their durability.



Adam's Hand is a myoelectric hand prosthesis. A single motor allows you to move all your fingers, automatically adapting them to the shape and size of the objects being handled



Complexdata has developed a platform that uses artificial intelligence to estimate the risk of metastasis in cancer patients.



Diamante specializes in the production of nanoparticles for the diagnosis of autoimmune diseases through the exploitation of plants as compounds with high added value.



eVAI is cloud platform developed by enGenome to support geneticists in the diagnosis of hereditary diseases from NGS data.



Genoa Instruments, will produce high-tech scientific instruments in the field of super-resolution optical microscopy.



Holey has created a solution capable of producing custom-made 3D printable orthopedic braces, which can replace both traditional plaster and commercial braces.



MgShell developed a solution to treat maculopathy capable of timing the drug release, therefore reducing the therapeutic load from several injections to a single injection.


P4P produces innovative polymeric biomaterials processed with additive manufacturing techniques to obtain advanced systems for the personalized administration of drugs.


RELIEF has created a minimally invasive endourethral device that can be inserted into the urethra of patients with severe incontinence and can be activated with a small magnet.
137 applications have been received for the second call of G-Factor, Life Sciences Innovation 2020: 24 of these have reached the final stage and 5 have been selected to participate in the acceleration process which will end in December 2020 with the awaited Investor Day. Each Startup will receive an investment of €125,000 of which € 90,000 of liquidity and € 35,000 in kinds.


Thanks to a patented biotechnology, Bacfarm produces deinoxanthin, the most powerful antioxidant among carotenoids and UV shield.



Innovative and unique CTC single cell blood analysis, disposable microfluidic analysis device, single cell analysis, image sorting and archiving.



An innovative biosensor for prostate cancer to reduce the number of unnecessary tests, costs, waiting times and inconvenience for the patient.



Micro-ReSkin is a PerFormS product developed to meet the needs of patients with acute, or chronic skin inflammations such as psoriasis.



RECORNEA has developed a revolutionary solution. With a single device and in a single step it managed to improve her eyesight and stop the progression of the keratoconus.



BCI deals with the biocompatibility of cardiac valve substitutes manufactured with animal tissues, improving their performance and doubling their durability.



Adam's Hand is a myoelectric hand prosthesis. A single motor allows you to move all your fingers, automatically adapting them to the shape and size of the objects being handled



Complexdata has developed a platform that uses artificial intelligence to estimate the risk of metastasis in cancer patients.



Diamante specializes in the production of nanoparticles for the diagnosis of autoimmune diseases through the exploitation of plants as compounds with high added value.



eVAI is cloud platform developed by enGenome to support geneticists in the diagnosis of hereditary diseases from NGS data.



Genoa Instruments, will produce high-tech scientific instruments in the field of super-resolution optical microscopy.



Holey has created a solution capable of producing custom-made 3D printable orthopedic braces, which can replace both traditional plaster and commercial braces.



MgShell developed a solution to treat maculopathy capable of timing the drug release, therefore reducing the therapeutic load from several injections to a single injection.


P4P produces innovative polymeric biomaterials processed with additive manufacturing techniques to obtain advanced systems for the personalized administration of drugs.


RELIEF has created a minimally invasive endourethral device that can be inserted into the urethra of patients with severe incontinence and can be activated with a small magnet.


Thanks to a patented biotechnology, Bacfarm produces deinoxanthin, the most powerful antioxidant among carotenoids and UV shield.



Innovative and unique CTC single cell blood analysis, disposable microfluidic analysis device, single cell analysis, image sorting and archiving.



An innovative biosensor for prostate cancer to reduce the number of unnecessary tests, costs, waiting times and inconvenience for the patient.



Micro-ReSkin is a PerFormS product developed to meet the needs of patients with acute, or chronic skin inflammations such as psoriasis.



RECORNEA has developed a revolutionary solution. With a single device and in a single step it managed to improve her eyesight and stop the progression of the keratoconus.

Team

Ing. Antonio Danieli
Director General and Board Member
@ Fondazione Golinelli
CEO @ G-Factor Incubator-Accelerator

Dott.ssa Cristiana Vignoli
Director @ G-Factor Incubator-Accelerator
c.vignoli@fondazionegolinelli.it


Subscribe to our newsletter
Be the first to get news and updates on our programs and events
Contact Us
How can we help you?
Do we already have to be a company to apply or can we set up at a later date if we are selected?
The company setup is necessary to receive the investment and to sign the initial programme agreement. You can therefore also apply as a team without being formally a company, but you must set up the company immediately after winning the tender, i.e. by 12 April 2021.
How long does the Acceleration Programme last?
The programme has a total duration of eight months; it includes an initial phase of intensive activities lasting three months (from 12 April 2021 to 1 July 2021), with two residential weeks to be attended in Bologna at the beginning of the programme, with the aim of accompanying the teams to introduce themselves to potential industrial partners. This first phase is followed by a period of a further five months of remote mentoring and follow-up (from 1 July to 16 December 2021), with the aim of accompanying the teams in their introduction to potential investors and when undertaking subsequent phases of growth and development.
How often do the intensive programme days occur in the first three months and how are they structured?
Attendance is daily, from Monday to Thursday. A standard day consists of a couple of hours of face-to-face classes in the morning and the rest of the time is taken up with one-to-one meetings with our mentors. We will also organise interventions of entrepreneurs, investors and innovators of international standing.
Does the whole team have to participate in the two residential weeks?
The presence of at least two team members is required, even if they are not always the same ones. At least one of the two members must have a role as CEO, CTO or COO in the start-up.
During the residential programme, what arrangements are made for accommodation?
During the initial two weeks in which your presence is requested, free accommodation is provided in Bologna in a partner structure for two team members from Monday to Thursday.
How many members must the team be made up of?
A team is made up of at least two members; there is no maximum limit.
How will resources be distributed in the Life Science & Digital Health Call for Innovation?
The resources will be distributed by G-Factor S.r.l. to each business project, as a gradual and progressive investment in equity, according to the means agreed with the selected teams, in three steps: a sum of 30,000 Euros in cash, at the start after the signing of the G-Factor Programme Agreement; a sum of 30,000 Euros in cash, after three months from the selection and the positive verification during the Demo Day of the progress of the work foreseen in the G-Force Programme Agreement; a sum of 30,000 euros in cash, after eight months from the start of the G-Force Programme, upon achieving the final milestones shared in the Programme Agreement and following the presentation of the business projects during the Investor Day.
How will resources be distributed in the FinTech & InsurTech Call for Innovation?
The resources will be distributed by CRIF S.p.a. to each business project, as a gradual and progressive investment in equity, according to the means agreed with the selected teams, in three steps: a sum of 30,000 Euros in cash, at the start after the signing of the G-Force Programme Agreement; a sum of 30,000 Euros in cash, after three months from the selection and positive verification during the Demo Day of the progress of the work foreseen in the G-Force Programme Agreement; a sum of 20,000 Euros in cash, after eight months from the start of the G-Force Programme, upon achieving the final milestones shared in the Programme Agreement and following the presentation of the business projects during the Investor Day.
How will resources be distributed in the AgriTech & FoodTech Call for Innovation?
The resources will be distributed by CRIF S.p.a. to each business project, as a gradual and progressive investment in equity, according to the means agreed with the selected teams, in three steps: a sum of 30,000 Euros in cash, at the start after the signing of the G-Force Programme Agreement; a sum of 30,000 Euros in cash, after three months from the selection and positive verification during the Demo Day of the progress of the work foreseen in the G-Force Programme Agreement; a sum of 20,000 Euros in cash, after eight months from the start of the G-Force Programme, upon achieving the final milestones shared in the Programme Agreement and following the presentation of the business projects during the Investor Day.
What expenses may be supported with the money provided if you are selected?
The selected start-up can use the resources for the purposes of the business project. In the FinTech & InsurTech and AgriTech & FoodTech Calls for Innovation, there will be a periodical accounting in order to verify that there are no expense items not strictly related to the business project.
Will the sum of money paid to the start-up have to be returned?
No, under no circumstances will a refund of the amount of money paid during the Acceleration Programme be requested. If the conditions of the Acceleration Programme are not met, the financing partners may decide to discontinue the proposed financing.
Can we use a different pitch deck model, or is it mandatory to use your template?
You can use your own model. The important thing is that it contains the information in our template.
I can’t view the application form on Gust correctly and/or I can't fill it in. What should I do?
To complete your application you need to use Google Chrome as your browser. Other browsers (Safari, Edge, Mozilla, etc...) may cause problems.
In what language should I complete my application on Gust?
If you are Italian you are required to fill in the application in Italian, but if you already have some material in English you can use it. Non-Italians may use English.
Is it compulsory to upload a video?
Yes, it’s compulsory. You don’t need a professional video, even a video made with a simple smartphone, in which you explain your project and present the team.
I have more than 50 publications. Do I have to attach them all?
You may attach a complete list of publications along with the five most relevant and/or most project-related publications for which you are applying.
We would like to apply, but in our team we are all over 40. What can we do?
To participate in the Call, at least one team member must be under 40. If you feel it is appropriate and you have an employee under 40 you would like to include in the team, you can apply as a team (and not as a start-up) by integrating the member under 40. If you are selected, you will need to include the under-40 member in the start-up in order to access the programme.
To participate in the Call, you must sign an intellectual property release, granting you “a non-exclusive, irrevocable, sub-transferable, worldwide, royalty-free license” to the content we upload to Gust. Why?
This disclaimer is necessary in order to use your data in the selection process. Any information you upload to Gust can only be used by G-Factor/CRIF within the I-Tech Innovation Programme 2021 for the Call you apply to. It cannot be used in any other way. Evaluators who participate in the selection process will all be bound by NDA with G-Factor/CRIF.
In the privacy statement, you ask for permission to give our contact details to third parties. Why?
It is not mandatory for you to accept this clause in order to apply. We ask to be able to transfer your data to third parties simply so that we can share it within our own network of partners and investors.
In which language will the intensive programme be delivered?
The programme will be mainly in Italian, except for mentorships and talks or with international guests, which will be in English.
Is there a reimbursement of expenses for the intensive programme?
No, no kind of reimbursement is foreseen.
PRIVACY POLICY
(pursuant to arts. 13 and 14 of Regulation (EU) 2016/679/EU GDPR
(1) Legal Basis
The General Data Protection Regulation (EU) 2016/679 (GDPR) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, in particular articles 13 and 14 of the Regulation, (hereinafter referred to as 'GDPR') aims to ensure that data processing is carried out in respect of fundamental rights and freedoms, as well as the dignity of individuals, with specific regard to confidentiality and personal identity.
The GDPR provides that the data subject or person from whom the data is collected are provided with a set of information regarding the purposes and modalities of how their data is processed.
(2) Data Controller
Under the GDPR, G-FACTOR S.r.L, a single partner company, with its registered office in Bologna (BO), Via Paolo Nanni Costa n. 14, with fiscal code 03710391206,
email address: privacy@g-factor.it. (hereinafter referred to as the Data Controller) – is the Data Controller of the personal data disclosed in the following form in order to receive the requested newsleter. You may request the complete list of data processing managers (both internal and external) by sending us a simple email at privacy@g-factor.it.
(3) Type of Data Collected
The Data Controller will only process the personal and contact details that you have disclosed compiling form in order to receive the requested newsletter. The legal basis for the processing of this data is compliance of the GDPR (art. 6.1-b of the Regulation) or, as applicable, by your express and voluntary consent to the processing of your personal data for one or more specific purposes (art. 6.1-a of the Regulation).
(4) Failure to Communicate Data
The transfer of your personal data, as Data Subject, is optional, however, failure to supply such data implies the impossibility of receiving the requested newsletter.
(5) Purpose of Data Processing
The Data Controller shall ensure that all data collected through the newsletter subscription form will be processed exclusively for the purposes of sending you information via our newsletter service where you have requested to receive information regarding the activities organized by (or in collaboration with) the Data Controller
(6) Recipients of Personal Data
Your personal data may be shared with:
• subjects, public and private individuals that, if strictly determined by law, will be able to access the data under legal provisions, within the limits provided by the same regulations (including but not limited to: tax authorities, etc.);
• subjects who need to access your data to conduct ancillary activities for the relation between the Data Subject and the Data Controller, within the limits strictly necessary to carry out the ancillary tasks entrusted to them;
• appointed personnel of the Data Controller, who have the duty of confidentiality and security of the processing of personal data.
• any supplier of the Data Controller, with whom it may establish relations for the administration, communication or management of the working relationship.
In any case, your personal data will not be subject to dissemination or, except as indicated above, communicated to third parties.
(7) Personal Data Processing Modalities
The data processing indicated in this privacy information notice is also carried out with the aid of electronic and/or IT devices, workstations (computers and laptops) connected to a network server, and other tools that ensure the adequate security and confidentiality of the processed information. The physical, logistic, and communications security measures applied also guarantee the non-interference of the processed data for the various purposes, including the limited access to only authorized individuals for each activity of any working relationship with the Data Controller.
(8) Rights of Data Subjects
The GDPR confers specific rights that can be exercised by you, as Data Subject, including obtaining the confirmation of the existence or absence of your personal data, even if not yet registered, details, in comprehensible form, of the data which are being processed and information concerning the source of the data, as well as the purpose of the data processing, in particular you have the right to obtain:
· confirmation that your personal data is being, has not been or has been processed, and if processed, the right to obtain access to it (right of access by the data subject, pursuant to art. 15 GDPR);
· the correction of inaccurate personal data, or the inclusion of incomplete personal data (right of rectification, pursuant to art. 16 GDPR);
· the erasure of personal data concerning the data subject without undue delay when of the grounds provided for in the Regulation applies (right to erasure or ‘right to be forgotten’, pursuant to art. 17 GDPR)
· the restriction of processing personal data when one of the grounds provided for in the Regulation applies (right to restriction of processing, pursuant to art. 18 GDPR);
· the complete and up-to-date list of all authorized for the processing of your personal data
(9) Protection of Personal Data
The Data Controller uses advanced security technologies and performs the periodic backup of stored information, to protect the integrity and confidentiality of your data.
(10) Retention of Personal Data
The Data Controller will retain your personal data for as long as necessary to fulfill the obligations required by law, resolve disputes and enforce the agreements concluded.
Your personal data will thus be retained, as provided by law, for a period of time not exceeding which is necessary to achieve the purposes for which they are processed. In any case, all care will be applied to avoid an excessive retention of your data, proceeding periodically to verify our archives.
(11) Information
You may exercise the above mentioned rights at any time by submitting a simple request to this email address privacy@g-factor.it or to the physical address indicated in the paragraph Data Controller. We will contact you as soon as possible, within 30 (thirty) days from the date of your request.
(12) Complaints
If you believe that the personal data protection legislation has been violated with regard to the processing of your data, you also have the right to file a complaint before the local authority for the protection of personal data within the European Economic Area. You may find the references of the individual authorities, depending on the country where you are located, by clicking on this link http://www.garanteprivacy.it/web/guest/home/footer/link.
***